These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
231 related items for PubMed ID: 23810957
21. The cysteinyl-leukotriene-1 receptor antagonist zafirlukast is a potent secretagogue in rat and human airways. Schmidt R, Staats P, Groneberg DA, Wagner U. Eur J Pharmacol; 2005 Dec 19; 527(1-3):150-6. PubMed ID: 16310765 [Abstract] [Full Text] [Related]
22. [The effect of montelukast on airway remodeling and the expression of interleukins and transforming growth factor-beta2 mRNA]. Bai JW, Deng WW, Wu HC. Zhonghua Jie He He Hu Xi Za Zhi; 2004 Aug 19; 27(8):524-8. PubMed ID: 15388000 [Abstract] [Full Text] [Related]
23. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties. Hegde SS, Hughes AD, Chen Y, Steinfeld T, Jasper JR, Lee TW, McNamara A, Martin WJ, Pulido-Rios MT, Mammen M. J Pharmacol Exp Ther; 2014 Oct 19; 351(1):190-9. PubMed ID: 25100753 [Abstract] [Full Text] [Related]
24. Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone. Murai A, Abe M, Hayashi Y, Sakata N, Katsuragi T, Tanaka K. J Pharmacol Exp Ther; 2005 Feb 19; 312(2):432-40. PubMed ID: 15470084 [Abstract] [Full Text] [Related]
25. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hutchinson AW, Gauthier JY, Lord A, Masson P. Can J Physiol Pharmacol; 1995 Feb 19; 73(2):191-201. PubMed ID: 7621356 [Abstract] [Full Text] [Related]
26. Oral montelukast treatment of preschool-aged children with acute asthma. Harmanci K, Bakirtas A, Turktas I, Degim T. Ann Allergy Asthma Immunol; 2006 May 19; 96(5):731-5. PubMed ID: 16729788 [Abstract] [Full Text] [Related]
27. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Shimbori C, Shiota N, Okunishi H. Eur J Pharmacol; 2011 Jan 10; 650(1):424-30. PubMed ID: 21034736 [Abstract] [Full Text] [Related]
34. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. Ikeda G, Miyahara N, Koga H, Fuchimoto Y, Waseda K, Kurimoto E, Taniguchi A, Tanimoto Y, Kataoka M, Tanimoto M, Kanehiro A. Am J Respir Cell Mol Biol; 2014 Jan 10; 50(1):18-29. PubMed ID: 23937413 [Abstract] [Full Text] [Related]
35. Montelukast inhibits inflammatory responses in small airways of the Guinea-pig. Harrison S, Gatti R, Baraldo S, Oliani KL, Andre E, Trevisani M, Gazzieri D, Saetta M, Geppetti P. Pulm Pharmacol Ther; 2008 Jan 10; 21(2):317-23. PubMed ID: 17905619 [Abstract] [Full Text] [Related]
36. TPI 1020, a novel anti-inflammatory, nitric oxide donating compound, potentiates the bronchodilator effects of salbutamol in conscious guinea-pigs. Turner DL, Ferrari N, Ford WR, Kidd EJ, Paquet L, Renzi P, Broadley KJ. Eur J Pharmacol; 2010 Sep 01; 641(2-3):213-9. PubMed ID: 20639142 [Abstract] [Full Text] [Related]
40. A comparison between clenbuterol, salbutamol and terbutaline in relation to receptor binding and in vitro relaxation of equine tracheal muscle. Törneke K, Ingvast Larsson C, Appelgren LE. J Vet Pharmacol Ther; 1998 Oct 01; 21(5):388-92. PubMed ID: 9811440 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]